Replimune Group (NASDAQ:REPL) Sets New 52-Week High – Here’s Why

Replimune Group, Inc. (NASDAQ:REPL)’s stock price hit a new 52-week high during mid-day trading on Monday. The company traded as high as $22.22 and last traded at $22.4440, with a volume of 248,937 shares traded. The stock had previously closed at $21.62.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on REPL. Wall Street Zen upgraded shares of Replimune Group from a “sell” rating to a “hold” rating in a research report on Saturday, October 31st. Leerink Partners raised their price objective on Replimune Group from $19.00 to $31.00 and gave the stock an “outperform” rating in a research note on Thursday, October 29th. Wedbush raised Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 price objective for the company in a report on Friday, August 7th. Weiss Ratings downgraded Replimune Group from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 11th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Replimune Group in a report on Monday, October 5th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $14.33.

Replimune Group Stock Up 3.7%

The company has a market capitalization of $2.13 billion, a P/E ratio of -8.04 and a beta of 0.93. The company has a debt-to-equity ratio of 0.59, a quick ratio of 6.90 and a current ratio of 7.11. The firm’s fifty day moving average is $14.09 and its 200-day moving average is $9.67.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Wednesday, October 28th. The company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.24. As a group, equities research analysts predict that Replimune Group, Inc. will post -2.40 EPS for the current year.

Insider Transactions at Replimune Group

In other Replimune Group news, CFO Emily Hill sold 9,256 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $14.28, for a total value of $132,175.68. Following the completion of the transaction, the chief financial officer directly owned 215,852 shares in the company, valued at approximately $3,082,366.56. This represents a 4.11% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kapil Dhingra sold 21,500 shares of the firm’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $19.00, for a total transaction of $408,500.00. Following the transaction, the director directly owned 21,669 shares of the company’s stock, valued at $411,711. The trade was a 49.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 5.40% of the company’s stock.

Institutional Trading of Replimune Group

Institutional investors have recently modified their holdings of the business. BlackRock Inc. acquired a new stake in Replimune Group in the second quarter valued at $99,171,000. Montanova Capital LLC raised its position in Replimune Group by 4.0% during the 2nd quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock worth $48,595,000 after purchasing an additional 168,000 shares during the last quarter. Opaleye Management Inc. bought a new position in Replimune Group during the 2nd quarter worth $15,332,000. Dimensional Fund Advisors LP lifted its holdings in Replimune Group by 1.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,140,099 shares of the company’s stock worth $8,719,000 after buying an additional 20,742 shares during the period. Finally, EcoR1 Capital LLC acquired a new position in Replimune Group during the 1st quarter worth about $7,650,000. Institutional investors own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.

Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.